Prescription of anti-influenza drugs in Japan, 2014–2020: A retrospective study using open data from the national claims database
Open Access
- 4 October 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (10) , e0291673
Abstract
Background: Both physicians and patients are proactive towards managing seasonal influenza in Japan and six drugs are approved. Although many countries have national influenza surveillance systems, data on nationwide prescription practices of anti-influenza drugs are lacking. Therefore, we aimed to clarify the status of anti-influenza drug use in Japan by analyzing real-world data. Methods: This retrospective study analyzed open data from the National Database of Health Insurance Claims and Specific Health Checkups, which covers most claims data from national health insurance. We estimated the annual number of patients prescribed anti-influenza drugs, which drugs they were prescribed, the patients’ age and sex distribution, drug costs, and regional disparities for the period 2014–2020. Results: For 2014–2019, an estimated 6.7–13.4 million patients per year were prescribed anti-influenza drugs, with an annual cost of 22.3–48.0 billion JPY (Japanese Yen). In addition, 21.1–32.0 million rapid antigen tests were performed at a cost of 30.1–47.1 billion JPY. In 2017, laninamivir was the most frequently prescribed anti-influenza drug (48%), followed by oseltamivir (36%), while in 2018, the newly introduced baloxavir accounted for 40.8% of prescriptions. After the emergence of COVID-19, the estimated number of patients prescribed anti-influenza drugs in 2020 dropped to just 14,000. In 2018, 37.6% of prescriptions were for patients aged < 20 years compared with 12.2% for those aged ≥ 65 years. Prescriptions for inpatients accounted for 1.1%, and the proportion of prescriptions for inpatients increased with age, with men were more likely than women to be prescribed anti-influenza drugs while hospitalized. Conclusions: Based on our clarification of how influenza is clinically managed in Japan, future work should evaluate the clinical and economic aspects of proactively prescribing anti-influenza drugs.Keywords
All Related Versions
Funding Information
- National Center for Global Health and Medicine (19A1026 and 20A3001 and 23A3002)
This publication has 45 references indexed in Scilit:
- Evaluation of Estimated Number of Influenza Patients from National Sentinel Surveillance Using the National Database of Electronic Medical ClaimsJapanese Journal of Infectious Diseases, 2015
- Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory commentsBMJ, 2014
- Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory commentsBMJ, 2014
- A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseasesJournal of Infection and Chemotherapy, 2013
- Clinical Features of Infants Hospitalized for 2009 Pandemic Influenza A (H1N1) in JapanThe Pediatric Infectious Disease Journal, 2012
- Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children2012
- Widespread use of neuraminidase inhibitors in JapanJournal of Infection and Chemotherapy, 2011
- Acute hepatitis B in Japan: Incidence, clinical practices and health policyHepatology Research, 2010
- Long‐Acting Neuraminidase Inhibitor Laninamivir Octanoate versus Oseltamivir for Treatment of Influenza: A Double‐Blind, Randomized, Noninferiority Clinical TrialClinical Infectious Diseases, 2010
- Japanese Practicing Physicians' Relationships with Pharmaceutical Representatives: A National SurveyPLOS ONE, 2010